PDCD1 and neoplasm: Acquired progressing lesions were defined as pre-existing tumors that initially underwent tumor shrinkage by >30% from baseline but subsequently progressed on PD1 inhibitor or new metastases identified after 6 months of starting PD1 inhibitor.